Search | Clinical Trials Finder

Conditions: Prostate Cancer
Interventions: Degarelix 80 mg / Degarelix 80 mg, Degarelix 160 mg / Degarelix 160 mg, Leuprolide 7.5 mg / Degarelix 80 mg, Leuprolide 7.5 mg / Degarelix 160 mg; Drug
Lead sponsor: Ferring Pharmaceuticals; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 386 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 14
States / cities: Homewood, Alabama • Laguna Hills, California • Torrance, California + 11 more

Conditions: Breast Neoplasms, Invasive Breast Cancer, Estrogen-receptor-positive Breast Cancer, HER2-negative Breast Cancer
Interventions: (Z)-endoxifen, goserelin; Drug
Lead sponsor: Atossa Therapeutics, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 14
States / cities: Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 11 more

Conditions: Healthy Participants
Interventions: Ruxolitinib IR, Ruxolitinib XR; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 19 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Heroin Dependence, Opioid Dependence
Interventions: Naltrexone; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 55 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2021
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Alzheimer's Disease
Interventions: Bapineuzumab (AAB-001); Drug
Lead sponsor: JANSSEN Alzheimer Immunotherapy Research & Development, LLC; Industry
Eligibility: Not listed
Enrollment: 194 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 29
States / cities: Peoria, Arizona • Sun City, Arizona • Encino, California + 26 more

Conditions: Breast Cancer Female, Chemotherapy-induced Peripheral Neuropathy, Gait Disorders, Neurologic, Balance; Distorted, Muscle Weakness
Interventions: Gait/balance & resistive exercise; Behavioral
Lead sponsor: University of South Florida; Other
Eligibility: 21 Years and older · Female only
Enrollment: 312 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Acute Hepatic Porphyria, Acute Intermittent Porphyria, Porphyria, Acute Intermittent, Acute Porphyria, Hereditary Coproporphyria (HCP), Variegate Porphyria (VP), ALA Dehydratase Deficient Porphyria (ADP)
Interventions: Givosiran, Placebo; Drug
Lead sponsor: Alnylam Pharmaceuticals; Industry
Eligibility: 12 Years and older
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 10
States / cities: Little Rock, Arkansas • San Francisco, California • Boston, Massachusetts + 7 more

Conditions: Attention Deficit Hyperactivity Disorder
Interventions: Atomoxetine Hydrochloride, Methylphenidate Hydrochloride, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 6 Years to 12 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 1
States / cities: Scottsdale, Arizona

Conditions: Healthy
Interventions: Tapentadol ER 250-mg TRF tablet, Tapentadol ER 250-mg PR2 tablet; Drug
Lead sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Industry
Eligibility: 19 Years to 55 Years
Enrollment: 63 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Eosinophilic Esophagitis
Interventions: reslizumab; Drug
Lead sponsor: Ception Therapeutics; Industry
Eligibility: 5 Years and older
Enrollment: 190 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 34
States / cities: Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 30 more

Conditions: Healthy Volunteers
Interventions: Nifedipine 60 MG Extended Release Oral Tablet, omeprazole/sodium bicarbonate, SmartPill (TM); Drug · Device
Lead sponsor: Food and Drug Administration (FDA); Federal
Eligibility: 18 Years to 55 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Columbia, Missouri

Conditions: Bilateral Knee Osteoarthritis
Interventions: FX006 32 mg, TAcs 40 mg; Drug
Lead sponsor: Pacira Pharmaceuticals, Inc; Industry
Eligibility: 40 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 3
States / cities: Torrance, California • Rochester, New York • Duncansville, Pennsylvania

Conditions: Active Systemic Lupus Erythematosus
Interventions: Anifrolumab, Placebo; Biological · Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 559 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 62
States / cities: Birmingham, Alabama • El Cajon, California • Hemet, California + 50 more

Conditions: HIV-1/HBV Co-Infection
Interventions: B/F/TAF, Placebo to match DTG, Placebo to match F/TDF, DTG, F/TDF, Placebo to match B/F/TAF; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 244 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 4
States / cities: Ft. Pierce, Florida • West Palm Beach, Florida • Berkley, Michigan + 1 more

Conditions: ADHD
Interventions: methylphenidate HCl, Mixed amphetamine salts extended release; Drug
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 7 Years to 11 Years
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Brookline, Massachusetts

Conditions: Epilepsies, Myoclonic
Interventions: Placebo, Lorcaserin; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 2 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 25
States / cities: Birmingham, Alabama • Los Angeles, California • San Diego, California + 20 more

Conditions: Hepatitis C
Interventions: telaprevir; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 408 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 25
States / cities: Birmingham, Alabama • Coronado, California • Los Angeles, California + 22 more

Conditions: Diabetic Retinopathy
Interventions: Behavioral Activation; Behavioral
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 65 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 2
States / cities: Philadelphia, Pennsylvania

Conditions: Schizophrenia
Interventions: SEP-380135, Quinidine Gluconate; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Crohn Disease, Colitis, Ulcerative
Interventions: TEV-48574 Dose Regimen A, TEV-48574 Dose Regiment B; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D LLC; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 247 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2031
U.S. locations: 18
States / cities: San Diego, California • Kissimmee, Florida • Orlando, Florida + 15 more

Conditions: Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (MOGAD)
Interventions: Rozanolixizumab, Placebo; Drug · Other
Lead sponsor: UCB Biopharma SRL; Industry
Eligibility: 18 Years to 89 Years
Enrollment: 113 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 11
States / cities: Scottsdale, Arizona • Palo Alto, California • Aurora, Colorado + 8 more

Conditions: Painful Diabetic Neuropathy, Diabetic Neuropathy, Painful
Interventions: Long-Term Follow-Up of Patients who Received Engensis (VM202), Long-Term Follow-Up of Patients who Received Placebo; Genetic · Drug
Lead sponsor: Helixmith Co., Ltd.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 14
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Sacramento, California + 11 more

Conditions: Metabolism of Prostaglandin D2
Interventions: niacin, aspirin, PGD2; Dietary Supplement · Drug · Other
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Chronic Idiopathic Urticaria
Interventions: etanercept, placebo; Drug
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Salt Lake City, Utah

Search by objective public record fields.

A Long-term Extension Study Evaluating a One-Month Dosing Regimen of Degarelix in Prostate Cancer Requiring Androgen Ablation Therapy

(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer

A Study to Evaluate the Relative Bioavailability of Ruxolitinib Extended Release (XR) Tablets Compared With Ruxolitinib Immediate Release (IR) Tablets Administered Orally in Healthy Participants.

Biomarkers of Injectable Extended Release Naltrexone Treatment

AAB-001 (Bapineuzumab) Open-Label, Long-Term Extension Study in Patients With Mild to Moderate Alzheimer's Disease

Home-Based Physical Activity Intervention for Taxane-Induced CIPN

ENVISION: A Study to Evaluate the Efficacy and Safety of Givosiran (ALN-AS1) in Patients With Acute Hepatic Porphyrias (AHP)

Comparison of Atomoxetine Plus Either Comparator or Placebo in Children With ADHD Who Haven't Responded to Stimulant Therapy

A Study to Assess Bioequivalence of a New Tapentadol Extended-Release 250-mg Tablet With Respect to a Tapentadol Extended-Release 250-mg Tablet in Healthy Participants

Open-Label Extension Study of Reslizumab in Pediatric Subjects With Eosinophilic Esophagitis

Drug Interaction With Proton Pump Inhibitors for Nifedipine ER Tablets

Study to Compare Exposure of TA Following Administration of Either FX006 or TAcs in Patients With Bilateral Knee OA

Long Term Safety of Anifrolumab in Adult Subjects With Active Systemic Lupus Erythematosus

Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment Naive, HIV-1 and Hepatitis B Co-Infected Adults

EEG Biomarkers for ADHD Stimulant Treatment

A Study of Lorcaserin as Adjunctive Treatment in Participants With Dravet Syndrome

Virology Follow up Study in Subjects Previously Treated With Telaprevir

Collaborative Care for Depression and Diabetic Retinopathy in African Americans

A Trial to Test the Effects of Other Drugs on SEP-380135 in Healthy Men and Women

A Study to Evaluate the Long-Term Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn's Disease

A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Myelin Oligodendrocyte Glycoprotein (MOG) Antibody-associated Disease (MOGAD)

Extension of Phase 3 Gene Therapy for Painful Diabetic Neuropathy

Pathways of Eicosanoid Metabolism

Etanercept for the Treatment of Chronic Urticaria